You are here:
Treatment of Pulmonary Arterial Hypertension
No estimate possible yet
Registration application pending
Sotatercept
Lung diseases
New medicine (specialité)
Lung diseases other
MSD
Subcutaneous
Injection
Extramural (GVS)
Centralised (EMA)
New medicine with Priority Medicines (PRIME)
No
October 2023
November 2024
Yes
In oktober 2022 heeft de fabrikant bekend gemaakt dat de primaire eindpunten van de STELLAR studie zijn gehaald.
In de fase 2 studie werden er resultaten gevonden op de 60 minuten looptest. De resultaten uit de fase 3 studie worden nog afgewacht.
1 times every 3 weeks
0,7 mg/kg
NCT04576988 (STELLAR)
Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.
255 - 884
Market share is generally not included unless otherwise stated.
ntvg.nl
De prevalentie van PAH in Nederland is ongeveer 15-52 per 1 miljoen inwoners.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
fabrikant
There is currently no futher information available.
Understanding of expected market entry of innovative medicines